Response shares hit year peak before solid results
This article was originally published in Clinica
Executive Summary
Shares in molecular diagnostics firm Response Genetics reached their highest price of the year to date in the run-up to the company’s second-quarter results. Response’s shares climbed as high as $2.72 each on the Nasdaq on August 7, the stock’s best pricing since December 2008.